FindMyKOL

Akil Merchant, MD

Enriched profile

Cedars-Sinai Medical Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyHematology / OncologyFocusLymphoma Diagnosis and Treatment+4
Active KOLFindMyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2012–2026

Akil Merchant is a Lymphoma Diagnosis and Treatment physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 227 publications with 4,364 citations (h-index 32); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.

Data verified 23 Oct 2026

Overview

Updated 25 Oct 2026

Akil Merchant, M.D., is affiliated with Cedars-Sinai Medical Center. The public record shows 227 publications with 4,364 citations (h-index 32), centered on Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Acute Myeloid Leukemia Research. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 9 companies, 4 NIH-funded awards (2012–2026).

  • Most recent indexed publication: 2026 · Cancer research communications
  • Top research focus: Lymphoma Diagnosis and Treatment
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma5 trialsLymphoma, B-Cell3 trialsLeukemia (AML/ALL/CML/CLL)2 trialsLymphoma, Non-Hodgkin2 trialsHodgkin Disease2 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma2 trialsLymphoma, Follicular2 trialsMultiple Myeloma1 trialLymphoma, T-Cell, Peripheral1 trialLymphoma, T-Cell1 trialEnteropathy-Associated T-Cell Lymphoma1 trialHematologic Neoplasms1 trialLymphoma, Large B-Cell, Diffuse1 trialMDS / MPN1 trialLeukemia, Myeloid, Acute1 trialPhiladelphia Chromosome1 trialCOVID-19

Research focus

OpenAlex concept fingerprint
Lymphoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersAcute Myeloid Leukemia ResearchMultiple Myeloma Research and TreatmentsSARS-CoV-2 and COVID-19 Research

Drugs & molecules

across trials, industry payments and publications
Epkinlygeneric · EpcoritamabClinical trials—Industry payments40Publications—Breyanzigeneric · Lisocabtagene maraleucelClinical trials—Industry payments32Publications—Blincytogeneric · BlinatumomabClinical trials—Industry payments5Publications—Adcetrisgeneric · Brentuximab vedotinClinical trials—Industry payments1Publications—Elrexfiogeneric · ElranatamabClinical trials—Industry payments1Publications—Skyrizigeneric · RisankizumabClinical trials—Industry payments1Publications—Venclextageneric · VenetoclaxClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments41Genmab U.S., Inc.Clinical trials—Industry payments27Abbvie Inc.Clinical trials—Industry payments15Amgen Inc.Clinical trials—Industry payments5Incyte CorporationClinical trials—Industry payments3Alliance for Clinical Trials in OncologyClinical trials1Industry payments—Allogene TherapeuticsClinical trials1Industry payments—Becton, Dickinson and CompanyClinical trials—Industry payments1Joshua Sasine, MD, PhDClinical trials1Industry payments—National Cancer Institute (NCI)Clinical trials1Industry payments—Novartis Pharmaceuticals CorporationClinical trials—Industry payments1Pfizer Inc.Clinical trials—Industry payments1SWOG Cancer Research NetworkClinical trials1Industry payments—TerSera Therapeutics LLCClinical trials—Industry payments1University of Southern CaliforniaClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
227publications

Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.

4,364citations

Total citations across indexed works.

32h-index

Hirsch index (OpenAlex). i10-index 57.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials ↓
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 2012–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 25 Oct 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

All 6 trial records: search, sort and filter.Explore →

Industry payments

Updated 25 Oct 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 14 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    57.6%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor30.5%
    Valacyclovir100%
    Part D<11 patients
    Short-acting sulfonamides27.1%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients

  • Dermatology

    22%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22%
    Acyclovir100%
    Part D<11 patients

  • Metabolism & gastrointestinal

    20.3%
    Serotonin-3 Receptor Antagonist20.3%
    Ondansetron Hcl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 25 Oct 2026

4 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:

All 23 award records: search, sort and filter.Explore →

Congress activity

Updated 25 Oct 2026

46 congress contributions (2011–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:

All 46 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 25 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 19 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Targeting Hedgehog — a Cancer Stem Cell Pathway
    Article501 citations2010
    doi.org ↗
  2. 02
    Molecular Signatures of Proliferation and Quiescence in Hematopoietic Stem Cells
    Article362 citations2004
    doi.org ↗
  3. 03
    Hematopoietic Fingerprints: An Expression Database of Stem Cells and Their Progeny
    Article318 citations2007
    doi.org ↗
  4. 04
    Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
    Article225 citations2019
    doi.org ↗
  5. 05
    Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
    Article218 citations2017
    doi.org ↗
All 227 cited works: search, sort and filter.Explore →

Network

Updated 25 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Alexander M. Xu85Matthew Painschab48Yuri D. Fedoriw48Tamiwe Tomoka48Jenny Coelho48Satish Gopal48Sophia Maharry Roush48Marriam Mponda47Maurice Mulenga47Edwards Kasonkanji47Anthony Colombo45Albert R. Wielgus45Amon Chirwa45Peter Kühn33Imran N. Siddiqi31Noah M. Merin31Kevin R. Kelly28Kaijin Wu26Julian Olea26Karen L. Reckamp26Matt C. Coffey26Eduardo Fernandez Hernandez25Homa Dadrastoussi25Claudia Villa Celi24Steffan T. Nawrocki24Paul Fields23Jennifer S. Carew23Denice D Tsao-Wei23Gerard J. Nuovo23Ann Mohrbacher23Xuelian Chen23Susan C. Cheng22William H. Matsui22Jonathan G. Braun22Christian Steidl22Tomohiro Aoki22Joseph Cornelius Lownik21Dermot P.B. McGovern21Katsuyoshi Takata19Monirath Hav19

Background & recognition

Updated 25 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cedars-sinai.edu ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.